Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Pantaleo: Poxvirus-Based Vaccine Development |
| Strategy: | Combo: Protein & vector vaccines |
| Study Type: | Pre-Clinical NHP |
| Species: | Rhesus macaque |
| Stage: | Assays Completed |
| Study Start Date: | 2012-01-25 |
| Study Made Public: | 2016-11-10 |
Title
Evaluation and comparison of the safety and immunogenicity of prime-boost regimens combining different poxvirus vector-based and gp120 protein vaccines in non-human primates
Description
CAVD 281 (AUP 513) is a non-human primate study comparing NYVAC/ALVAC prime/boost regimens.
Sign in to see full information about this study and to download study data.
Products
NYVAC-C-KC-ΔB19R ALVAC (vCP1521) AIDSVAX B/E Alum MF59 NYVAC-C-Gag-Pol-Nef NYVAC-C-gp140 gp120 C.1086 gp120 TV1 NYVAC-KC-gp140(ZM96) NYVAC-KC-Gag(ZM96)Pol-Nef(CN54) NYVAC-KC-deltaB19-Gag(ZM96)Pol-Nef(CN54) ALVAC-Gag Pol Nef ALVAC-gp140Integrated data
BAMA, ICS, NAb
Non-integrated data
No non-integrated data is available for this study.